Bristol-Myers Squibb Company (BMY)

56.92
0.28 0.49
NYSE : Health Care
Prev Close 56.64
Open 56.69
Day Low/High 56.35 / 57.27
52 Wk Low/High 46.01 / 77.12
Volume 5.60M
Avg Volume 8.37M
Exchange NYSE
Shares Outstanding 1.65B
Market Cap 94.45B
EPS 2.70
P/E Ratio 19.91
Div & Yield 1.56 (2.70%)

Latest News

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Major Talc Case Against J&J Declared a Mistrial Following SCOTUS Ruling

Major Talc Case Against J&J Declared a Mistrial Following SCOTUS Ruling

The court ruled that state courts can't hear claims against an out-of-state company if the alleged injuries didn't occur there.

Bristol-Myers Squibb Announces The Expiration Of Its Cash Tender Offer

Bristol-Myers Squibb Company (NYSE:BMY) announced today the expiration, as of 5:00 p.

Bristol-Myers Squibb Announces The Pricing Terms Of Its Cash Tender Offer For Any And All Of Certain Of Its Outstanding Debt Securities

Bristol-Myers Squibb Company (NYSE:BMY) announced today the pricing terms of its previously announced cash tender offer for any and all of certain of its outstanding debt securities.

Bristol-Myers Squibb Is Poised for a Breakout

Bristol-Myers Squibb Is Poised for a Breakout

Shares of BMY finished Monday at new June highs and are now set up well for an upside breakout.

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.

On Betting Against the Bonds and Panicking off the Fed: Jim Cramer's Best Blog

On Betting Against the Bonds and Panicking off the Fed: Jim Cramer's Best Blog

Jim Cramer discusses bonds and also talks about why panicking off the Fed is a superbad idea.

Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response In Adult Patients With Relapsed Or Progressed Classical Hodgkin Lymphoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced extended follow-up data in which Opdivo (nivolumab) demonstrated responses in adult patients with relapsed or progressed classical Hodgkin lymphoma (cHL) after...

Cramer: You Can't Bet Against the Bonds

Cramer: You Can't Bet Against the Bonds

A rotation that started as the minor chord of the rotational symphony and is now the major one.

Bristol-Myers Squibb To Sell Manufacturing Facility In Swords, Ireland To SK Biotek Co., Ltd.

Bristol-Myers Squibb Company (NYSE:BMY) and SK Biotek Co.

Still Waiting for the All-Clear on FANG

Resist the urge to buy; their time will come again.

Seattle Genetics And Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Relapsed Hodgkin Lymphoma At The International Conference On Malignant Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) and Bristol-Myers Squibb Company (NYSE: BMY) today highlighted an updated interim analysis from the ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin)...

Bristol-Myers Squibb Announces Cash Tender Offer For Any And All Of Certain Of Its Outstanding Debt Securities

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has commenced a cash tender offer for any and all of its 5.

Bristol-Myers Squibb To Present New Research Related To The Treatment Of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease At The Annual European Congress Of Rheumatology (EULAR 2017)

Bristol-Myers Squibb Company (NYSE:BMY) today confirmed that 23 abstracts related to ORENCIA ® (abatacept), including new data on the role of biomarkers and MRI in RA patient identification and treatment, will be...

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-nine cents ($0.

Bristol-Myers Squibb To Announce Results For Second Quarter 2017 On July 27

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2017 on Thursday, July 27, 2017.

Intermediate Level Trade: BMY

Intermediate Level Trade: BMY

I prefer a bullishly biased vertical call spread.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.

Bristol-Myers Squibb Announces Availability Of New ORENCIA® (abatacept) Subcutaneous Administration Option For Patients 2 Years Of Age And Older With Moderately To Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

Bristol-Myers Squibb Company (NYSE:BMY) announced today the availability of a new FDA-approved subcutaneous (SC) ORENCIA administration option for use in patients 2 years of age and older with moderately to severely active...

Cramer: 15 Stocks to Buy for the Triathlon of Fear Coming on Super-Thursday

Cramer: 15 Stocks to Buy for the Triathlon of Fear Coming on Super-Thursday

The handwringers will be out in full force. Their fear creates buying opportunities.

Bristol-Myers Squibb To Take Part In Goldman Sachs 38th Annual Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in Goldman Sachs 38 th Annual Global Healthcare Conference on Wednesday, June 14, 2017, in Rancho Palos Verdes, CA.

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol-Myers will conduct the study and both companies will evaluate the findings.

Bristol-Myers Squibb Announces New Collaboration To Evaluate Combination Therapy In Colorectal Cancer

Bristol-Myers Squibb Company (NYSE:BMY) announced today it has entered into a clinical research collaboration with Novartis to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo +...

Clinical Trial Data For Combination Of Epacadostat And Opdivo® (nivolumab) Demonstrate Durable Clinical Responses In Patients With Melanoma And Head And Neck Cancer

Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's investigational...

Encouraging Disease Control Rates Observed With Nivolumab Alone Or In Combination With Ipilimumab In Refractory Or Relapsing Malignant Pleural Mesothelioma Patients: Results From IFCT-1501 MAPS-2 Trial

The French Cooperative Thoracic Intergroup (IFCT) and Bristol-Myers Squibb Company (BMS) (NYSE:BMY) announced today results from the IFCT-1501 MAPS-2 trial evaluating the safety and efficacy of nivolumab or nivolumab...

Early, Durable Responses Seen With Sprycel (dasatinib) In First- And Second-Line Treatment Of Pediatric Patients With Chronic Myeloid Leukemia In Chronic Phase (CP-CML)

Bristol-Myers Squibb Company (NYSE: BMY) today announced the first presentation of data from two cohorts of the Phase 2 CA180-226 clinical trial evaluating Sprycel (dasatinib) in imatinib-resistant or -intolerant (R/I to...

New Data Evaluating the Safety And Preliminary Relapse-Free Survival Of Adjuvant Yervoy (ipilimumab) 3 Mg/kg And 10 Mg/kg In Resected High-Risk Melanoma Patients Presented At ASCO

Bristol-Myers Squibb Company (NYSE:BMY) today announced results of an interim descriptive analysis from an ongoing National Cancer Institute (NCI) Phase 3 randomized study evaluating Yervoy (ipilimumab) 3 mg/kg and...

First Presentation Of Efficacy Data From CheckMate -204 Evaluating The Combination Of Opdivo (nivolumab) And Yervoy (ipilimumab) Demonstrates Anti-tumor Activity In Advanced Melanoma Patients With Brain Metastases

Bristol-Myers Squibb Company (NYSE:BMY) today announced efficacy and safety data from CheckMate -204, the first Phase 2 study to evaluate Opdivo plus Yervoy as a potential treatment for patients with melanoma...